Pacmilimab
Based on 1 Customer Validation
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 95.00%
- CAS No.: 2145091-51-4
- Masse moléculaire:152.6 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
B7-H1/PD-L1/CD274
In Vivo
Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Product Details
-
CAS No. 2145091-51-4
-
Accession Q9NZQ7
-
Synonyms CX-072
-
Masse moléculaire 152.6 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG4 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG4 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureté
95.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Livraison
Shipping with dry ice.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)